

## **ODR Update for Use My Data**

## Improving the speed of data access

The ODR has continued to improve the efficiency of its service to reduce the lead time from submission of a complete application to data release. During the first 6 months of this financial year (April – October 2019), the average elapsed time from ODR receiving a complete application to data being sent to the applicant was 48 working days. This is an improvement to the previous year and ODR is committed to reducing this further.

## **Enabling access**

ODR runs regular training webinars to help applicants navigate the data access process. The "ODR approval explained: applying for and accessing PHE data" sessions are run throughout the year. In addition, we now provide sessions aimed specifically at research sponsors "Setting up for success: how sponsors can support ODR applications". The first of this type of webinar was run earlier this month and feedback has been very positive. ODR will ensure more sponsor focussed sessions are provided in the future.

PHE in partnership with NCRI have appointed a NCRI/PHE Cancer Data Access Manager. Their role is to provide a bridge between the cancer research community and cancer registration data to improve access to data that can be used to develop and inform clinical trials and other high quality research projects which span the cancer journey.


## Improving transparency

ODR continues to work with stakeholders to improve public understanding of who PHE data is released to and for what purpose. The PHE Data Release Register was updated and published in September 2019 to include releases made from 1 April 2019 – 31 July 2019. For this period, all published releases were accompanied by a lay summary. Work will commence next year to further develop the release register into a more user friendly and accessible tool for the public.

The PHE Independent Advisory Panel on Data Release have met 3 times this financial year (4th meeting due in December). Their role is to provide the PHE Data Release Assurance Board with authoritative and independent advice and recommendations regarding data release. For more details please see: <a href="https://www.gov.uk/government/publications/accessing-public-health-england-data/independent-advisory-panel-on-data-release">https://www.gov.uk/government/publications/accessing-public-health-england-data/independent-advisory-panel-on-data-release</a>

General information on ODR activity for the first 6 months of this financial year (April – October 2019)

Distribution of data releases by secondary use type:



Proportion of customers, by organisation type, contacting the ODR to seek pre-application advice or to submit an application or amendment for ODR approval:

